<DOC>
	<DOC>NCT00698802</DOC>
	<brief_summary>This trial is conducted in Asia and Africa. This trial aims for a comparison of blood glucose control of biphasic human insulin 100 IU/mL and EX1000.</brief_summary>
	<brief_title>Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes for at least 12 months Current biphasic human insulin (BHI) for at least 3 months as monotherapy or as the only insulin in combination with OADs Body Mass Index (BMI) less than or equal to 40.0 kg/m2 HbA1c less than or equal to 9.5% FPG (SMPG) less than or equal to 12 mmol/L Treatment with more than 1IU/kg insulin daily Treatment with Glucagonlike peptide 1 mimetics or dipeptityl peptidase IV inhibitors Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator Known or suspected allergy to trial products or related products Receipt of any investigational drug within one month prior to this trial Any other condition that the Investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>